Otolith Labs
Otolith Labs is pioneering the first medical wearable for the treatment of chronic vertigo, a symptom experienced by 11.6 million Americans. The company utilizes patented non-invasive technology to provide relief from vertigo symptoms, aiming to improve the quality of life for those affected by vestibular disorders.
Otolith Labs
200 Massachusetts Ave NW, Floor 7, Washington, DC 20001
What We Do
A non-invasive therapy designed to reduce symptoms of chronic vertigo through precision signals that interact with the vestibular system.
A compact, headworn device that applies localized nVRT stimulation to manage vertigo symptoms without the need for surgery or complex fittings.
Key People
News & Updates
Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.
Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.
Technical.ly interviews Otolith’s CEO Sam Owen about the pressing need for a new treatment option for chronic vertigo.
Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving 'Breakthrough Device' Designation from FDA.